Prostate Cancer

Clinicians noted that symptoms—bone pain, declining function, anemia, and renal compromise—carry significant weight when choosing therapy.

The approval is supported by 12-month data from the prospective VAPOR 2 trial.

A recap of the FDA submissions and regulatory decisions in urology from November 2025.

The test is intended to aid in the decision for prostate biopsy in men aged 50 years or older who present with elevated PSA levels.

According to the authors, the optimal duration of treatment could be tied to individual patient factors such as cancer risk.

The clearance supports new ultrasound imaging and workflow enhancements to the Focal One i, which was launched earlier this year.

The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.

A major portion of the discussion focused on selecting among ARPIs for use with ADT in the mCSPC setting.

Henderson emphasized the evolving role of advanced biomarkers in refining prostate cancer risk assessment beyond traditional PSA testing

The phase 1b trial is assessing ORIC-944 both in combination with darolutamide and apalutamide.

Collins stresses the oncological importance of local control, as local recurrences can lead to a "second wave of metastatic disease" that can ultimately cause death.

Alice Bernard-Tessier, MD, highlights preliminary results from a phase 1 trial of gedatolisib plus darolutamide in mCRPC.

"I think MRI has really been perhaps the most transformative development in the realm of prostate cancer screening since I came into the field," says Stacy Loeb, MD, MSc, PhD (Hon.

"It's been a very exciting time for the radioligand space," says J. Travis Mendel, MD.

The rectal spacer showed sustained preservation of bowel, urinary, and sexual quality of life through 4 years of follow-up.

Panelists emphasized that the decision between doublet and triplet therapy must be individualized.

A major focus of the discussion was the growing role of darolutamide (Nubeqa) in the management of mCSPC.

212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy.

Bertrand Tombal, MD, PhD, shares insights from the real-world REASSURE trial.

The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.

A recap of the FDA submissions and regulatory decisions in urology from October 2025.

Monique Roobol, PhD, MSc, noted that approximately half of the 30% higher incidence of prostate cancer in the screened arm represents overdiagnosis, primarily of low-risk cancers.

The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure.

Pedro C. Barata, MD, MSc, FACP, outlines ARANOTE findings stratified by age subgroups.

Louise K. Kostos, MBBS, FRACP, PhD candidate, outlines initial findings from the phase 1/2 AlphaBet trial.